Amgen's BLINCYTO® Improves Survival in Pediatric B-Cell ALL: AALL1731 Results at ASH24

Dec 8, 2024, 02:04 PM

At the American Society of Hematology's (ASH) 2024 Annual Meeting (#ASH24), significant clinical trial results were presented, highlighting advancements in the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). A key study presented by the Children's Oncology Group (COG) revealed that the addition of blinatumomab, marketed as BLINCYTO® by Amgen, to induction chemotherapy significantly improved disease-free survival in children with standard-risk B-ALL. The full results of the AALL1731 trial demonstrated enhanced survival rates when blinatumomab was added to chemotherapy regimens for newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia.